Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Elena S. Koltun, Mallika Singh et al.|Nature|2024Cited by 319
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancerBiagio Ricciuti, Jia Luo, Bijaya Sharma et al.|Annals of Oncology|2022Cited by 100
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockadeMarie‐Julie Nokin, Chiara Ambrogio|Nature Communications|2024Cited by 54
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMallika Singh, David Wildes, Matthew Holderfield et al.|Research Square|2023Cited by 5
Abstract B025: The RAF/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of KRAS G12C and G12D inhibitors through vertical inhibition of RAS, RAF and MEK. </title>Silvia Coma, Jonathan A. Pachter, Mónica Musteanu et al.|Molecular Cancer Research|2023Cited by 3